Brief: LeMaitre Vascular Q2 Sales USD 64.232 Million Vs. IBES Estimate USD 62.5 Million

LeMaitre Vascular

05/08/2025 21:06

Overview

LeMaitre Vascular Inc Q2 sales rise 15% yr/yr, beating analyst expectations

EPS for Q2 up 16%, driven by higher sales and gross margin

Co raises 2025 guidance, reflecting confidence in sales and profit growth

Outlook

LeMaitre sees Q3 sales $61.2 mln to $63.2 mln

Company expects full-year sales $248 mln to $254 mln

LeMaitre projects Q3 EPS $0.54 to $0.59

Company anticipates full-year EPS $2.23 to $2.37

Result Drivers

CATHETERS AND GRAFTS - Catheters and grafts drove Q2 sales growth, increasing by 27% and 19% respectively

REGIONAL SALES GROWTH - EMEA sales increased by 23%, while Americas and APAC both grew by 12%

HIGHER SELLING PRICES - Gross margin improved to 70.0% due to higher average selling prices and manufacturing efficiencies

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$64.23 mln
$62.50 mln (10 Analysts)
Q2 Net Income
$13.78 mln
Q2 Gross Profit
$44.97 mln
Q2 Income From Operations
$16.14 mln
Q2 Pretax Profit
$18.07 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for LeMaitre Vascular Inc is $108.00, about 21.9% above its August 4 closing price of $84.36

The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 39 three months ago

Press Release: ID:nGNX5tkHqr

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)